There is currently no cure for the rare neurodegenerative disorder multiple system atrophy (MSA), and its rarity has made it difficult to understand how the disease progresses. Now a research team has ...

The Multiple System Atrophy Coalition was founded in 1989 as a Support Group offering a toll-free hotline and an annual patient/caregiver conference. The new name was chosen to better reflect the ...

Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, today announced publication of new peer-reviewed research in npj Parkinson's Disease, a ...

The multiple system atrophy clinical trial analysis report delivers important insights into ongoing research of 24+ pipeline multiple system atrophy drugs, clinical strategies, upcoming therapeutics, ...

The growth of the MSA market is attributed to the increasing research and developmental activities to develop disease modifying therapies for MSA. For instance, in 2020, Neuraly raised $15 million in ...

In a study published in Neuron, researchers have identified four new genetic risk factors for multiple system atrophy (MSA), shedding light on this poorly understood disorder. The study, which ...

Multiple system atrophy (MSA) is an atypical Parkinsonian disorder marked by oligodendroglial α-synucleinopathy and selective neurodegeneration. Although MRI can ...

Two devastating movement disorders, Parkinson’s disease and multiple system atrophy, often look so similar in the clinic that ...

HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...

Multiple System Atrophy (MSA) is a neurological disorder that is similar to Parkinson's with many overlapping symptoms, but is rarer and progresses at a faster rate. Research for treatment is limited, ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder characterised by a combination of parkinsonism, cerebellar ataxia and autonomic dysfunction. Clinical assessment ...